Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494662 · ClinicalTrials.gov registry record · Phase 2
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT01494662 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 140 participants.
The verdict
NCT01494662, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.
Interventions
- DRUG Capecitabine
- PROCEDURE Surgical Resection
- DRUG Ado-Trastuzumab Emtansine
- DRUG HKI-272
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2012-02 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494662
The ClinicalTrials.gov registry entry for NCT01494662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Capecitabine is the first listed.
NCT01494662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01494662 about?
NCT01494662 is a clinical study titled "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases". The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that ...
What is the current status of trial NCT01494662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2012-02. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT01494662?
The interventions under investigation include: Capecitabine (DRUG), Surgical Resection (PROCEDURE), Ado-Trastuzumab Emtansine (DRUG), HKI-272 (DRUG).
Who is sponsoring clinical trial NCT01494662?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.